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Acinetobacter baumannii is a nosocomial pathogen involved in various infections ranging 
from minor soft-tissue infections to more severe infections such as ventilator-associated 
pneumonia and bacteremia. The severity and the type of infections depend on the genetic 
and phenotypic variations of the strains. In this study, we compared the extent of biofilm 
formation and motility displayed by 60 multidrug-resistant A. baumannii clinical strains 
isolated from blood and sputum samples from patients from Southern India. Our results 
showed that isolates from the sputum samples formed significantly more robust biofilm 
compared to the blood isolates. On the other hand, we observed that the blood isolates 
were more motile than the sputum isolates. To the best of our knowledge, this is the first 
study that systematically evaluated the correlation between these two phenotypic traits 
and the nature of the isolates.
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inTrODUcTiOn
Acinetobacter baumannii is a nosocomial pathogen that can cause a wide array of infections ranging 
from minor skin and soft-tissue infections to more severe invasive diseases, such as bacteremia, 
meningitis, and ventilator-associated pneumonia (VAP). VAP typifies serious hospital-acquired 
infections due to colonization of A. baumannii in the airway via environmental exposure. The 
mortality rate associated with A. baumannii induced VAP is between 40 and 70% (1, 2). The patients 
with the highest mortality tend to be older, immunocompromised, have prolonged intubation, and 
are at a greater risk of infection by other pathogens. In the intensive care setting, A. baumannii 
also causes serious bloodstream infections (3). The pathogen primarily enters into the bloodstream 
through lower respiratory tract infections and intravascular devices (4–7). Wound and urinary 
tract infections also lead to bloodstream infections (4). Like VAP, the risk factors for bloodstream 
infections include among others immunosuppression, colonization with A. baumannii, and invasive 
procedures (6–8). The mortality rates associated with the A. baumannii bloodstream infections 
ranges between 28 and 43%; however, the issue is highly debatable (3, 4, 9–11).
The pathogen’s ability to survive and to persist for extended periods of time on surfaces makes 
it a frequent cause for health-care-associated infections. Moreover, emergence and spread of 
multiple drug resistance (MDR) A. baumannii is an area of great clinical concern. A. bauman-
nii is becoming resistant to most of the commonly used antibiotics, including aminoglycosides, 
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broad-spectrum-β-lactams, and quinolones (12–16). MDR- or 
pandrug-resistant strains pose challenges to any clinician treating 
the infections caused by these strains. The drug resistance also 
imposes an additional economic burden on health-care systems 
(16, 17). There is an urgent need for the development of novel 
strategies to control infections caused by A. baumannii.
Acinetobacter baumannii encodes multiple virulence factors 
that contribute to the pathogenesis of this organism. Among 
them, the ability to form robust biofilm is one of the key virulence 
attributes of this pathogen. Formation of biofilm requires expres-
sion of the CsuA/BABCDE chaperon–usher complex required 
for the assembly and production of pili involved in adhesion to 
abiotic surfaces (18). It has been shown that inactivation of just 
the csuE gene eliminates pili production and biofilm formation. 
The csu operon is controlled by a two-component system, BfmRS, 
and the inactivation of BfmR abolishes expression of this operon 
and therefore pili and biofilm formation (19). Some strains of 
A. baumannii also produce relatively short pili that are CsuA/
BABCD independent. These short pili are involved in the attach-
ment to biotic surfaces, such as human respiratory cells (20), 
whereas other A. baumannii strains, such as 307-0294, encode 
a cell-surface-associated protein, Bap, which is homologous 
to a staphylococcal protein, is important for the stabilization 
of mature biofilm on abiotic and biotic surfaces (21, 22). The 
cell-surface-associated protein OmpA also plays an important 
role in biofilm formation (23). A. baumannii secretes an extra-
cellular polysaccharide poly-β-(1, 6)-N-acetylglucosamine 
(PNAG) that functions as an intracellular adhesion among 
the biofilm-associated cells (24). A. baumannii has the ability 
to survive prolonged exposure to dry conditions and nutrient 
limiting environments (20, 25–28). This survival trait allows the 
organism to persist on the abiotic surfaces that are present in the 
health-care setting. The extraordinary survival ability has also 
been implicated to resistance to various antibiotics and desic-
cation (18, 26). Furthermore, it has also been proposed that the 
resistance phenotypes of the clinical isolates could be attributed 
to the ability form biofilm on abiotic surfaces, particularly the 
isolates from patient inserts (18, 29, 30). A recent study by 
Espinal and colleagues suggested that the clinical isolates that 
form higher biofilms tolerate and survive desiccation better than 
the non-biofilm forming clinical isolates (28).
Acinetobacter baumannii lacks flagella and has been described 
as non-motile (18, 31). Recent whole genome sequence analysis 
has also confirmed the absence of flagellar genes in A. baumannii 
suggesting the lack of true swarming motility, which requires 
flagella (32). However, several recent studies have demonstrated 
that A. baumannii displays twitching motility that allows the 
organism to spread rapidly on semisolid and certain abiotic 
surfaces (32–36). Twitching motility is mediated by type IV pili 
by the action of extension and retraction of the pili. The genes 
necessary for the assembly of type IV pili (pilA-C, pilF, pilM-Q, 
pilW, pilZ), twitching (pilR-T), and the pilin filament (pilA) are 
all present in the A. baumannii genome. Two groups have recently 
shown that type IV pili are necessary for both surface and twitch-
ing motility (32, 36). Furthermore, analysis of genome sequences 
suggests the presence of multiple type IV pili-associated genes in 
all the A. baumannii strains whose complete genome information 
is available. Moreover, a positive correlation between the PilA 
encoding gene and the degree of twitching motility has been 
demonstrated in clinical isolates (33). The motility in bacteria is 
regulated by multiple signal transduction pathways (37). Several 
environmental factors, such as light (particularly in the blue 
wavelength), iron availability, and stress, will influence the motil-
ity in A. baumannii (34, 38).
Although most of the studies involving clinical isolates 
focused on the biofilm formation or drug resistance, there is no 
systematic study to correlate between nature of the isolate with 
the biofilm and motility. In this study, we used 60 multidrug 
resistant clinical isolates that are from sputum and blood sam-
ples. We first determined the clonal lineage of these isolates and 
evaluated the synergistic activity of sulbactam with meropenem 
or colistin. We then investigated the capacity to form biofilm on 
polystyrene tubes and the twitching and surface motility of these 
clinical isolates. We found that sputum isolates tend to form more 
biofilm as compared to the blood isolates. On the other hand, 
blood isolates displayed more motility than the sputum isolates. 
This is the first systematic study to delineate the two important 
phenotypic traits with the origin of clinical isolates.
MaTerials anD MeThODs
Bacterial isolates and growth conditions
This study was conducted between January 2014 and June 2014 at 
Christian Medical College (CMC), Vellore, India. The 60 isolates 
investigated were obtained from the respiratory secretions, and 
blood samples of 60 patients attending different outpatient wards. 
The blood and the sputum isolates were from different cohort of 
patients. The protocol was reviewed by the Institutional Review 
Board (IRB), CMC, Vellore, and determined to meet the necessary 
criteria for exemption since the project falls under the category of 
observational study. Per local policies and through consultation 
with the IRB, written patient consent was not required and formal 
ethical approval was reviewed and waived.
The samples were sent to the Clinical Microbiology Department 
for further analysis. Gram-negative bacilli isolates were further 
identified as A. baumannii – Acinetobacter calcoaceticus complex 
and were confirmed by biochemical tests based on carbohydrate 
and amino acid utilization. Antimicrobial susceptibility was 
tested for all the isolates on Mueller–Hinton agar (BD), using 
the standard Kirby–Bauer disk diffusion method according to 
the guidelines of the Clinical and Laboratory Standards Institute 
(CLSI). The following antimicrobials were tested: amikacin 
(10 μg), aztreonam (10 μg), ciprofloxacin (10 μg), ceftazidime 
(10 μg), cefepime (10 μg), gentamicin (10 μg), imipenem (10 μg), 
meropenem (10 μg), piperacillin-tazobactam (10 μg), tobramycin 
(10 μg), and trimethoprim–sulfametoxazol (30 μg).
Metallo β-lactamase Detection
A freshly prepared bacterial suspension adjusted to 0.5 McFarland 
unit (1.5 ×  107  cells) was streaked for confluent growth on a 
Mueller–Hinton agar plate using a swab. Five microliters of 
EDTA (0.35M EDTA) solution were added into a paper disk 
(6 mm diameter) and dried without overflowing. The disks were 
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placed at the center of the plate. Ten micrograms of meropenem, 
meropenem with EDTA, cefepime, and cefepime with EDTA 
disks were placed at a distance of 10 mm from the center, and the 
plate was incubated at 37°C for 16–18 h. Disks containing EDTA 
alone served as the negative control. The appearance of zone 
around the antibiotics containing EDTA disks would indicate 
a metallo β-lactamase (MBL) producer. We consider an isolate 
to be MBL-positive if the zone of inhibition is larger than 2 mm 
when EDTA is added to the meropenem and cefeprime disks. The 
test was repeated at least three times.
Biofilm assay
Polystyrene (12  mm  ×  75  mm) tubes containing 1.5  ml of 
Mueller–Hinton broth was inoculated with 30 μl of an overnight 
liquid culture, and the tubes were incubated at 37°C for 48 h. The 
liquid media was discarded, and the adherent cells were washed 
twice with phosphate-buffered saline (PBS) and stained with 
0.02% of crystal violet for 10 min. The stain was eluted from the 
adherent cells using an ethanol:acetone (1:5) solvent and vortex-
ing for 5 min. Absorbance of the eluted solvent was measured, 
after diluting 10-fold with the solvent, at 580 nm using an UV 
visible spectrophotometer (UV-1601, SHIMADZU). The assay 
was done at least three times using fresh samples each time.
Motility assay
Modified LB broth (tryptone  –  10  g/l; NaCl  –  5  g/l; yeast 
extract – 5 g/l) with either 0.4 or 0.8% agar was used for all the 
motility assays. Freshly grown cultures were stabbed to enable 
spread of bacteria on the surface of the medium (0.4% semisolid) 
for swarming motility and the interphase between the bottom 
of the Petri dish and medium (0.8% semisolid) for twitching 
motility, as described previously (32). Plates were prepared on 
the same day as the inoculation. After inoculation, the plates were 
sealed with parafilm and incubated at 37°C for 48 h. Swarming 
positive isolates were defined as those strains that showed a zone 
of >10 mm around the site of inoculation. For twitching motility, 
the agar was discarded, and the plates were stained with 0.2% 
crystal violet before visualization and photographed. For each 
isolate, assays were performed at least three times.
antibiotic sensitivity assays
A microbroth dilution assay was used to determine MICs for 
sulbactam, meropenem, and colistin as per Clinical Laboratory 
Standard Institute guidelines. Checkerboard synergy was per-
formed and calculated using this formula. Fractional inhibitory 
concentrations (FICs) indices were calculated as (MIC of drug 
A or B in combination)/(MIC of drug A or B alone), and the 
FIC index was obtained by adding the FIC values. FIC indices 
were interpreted as synergistic if values were <0.5, additive or 
indifferent if 0.5–4.0 and antagonistic if >4.0. Time-kill assay was 
performed at ½ the MIC value for each drug. An antimicrobial 
solution at the required concentration was prepared in cation-
adjusted Mueller–Hinton broth at a final volume of 10  ml. An 
inoculum of approximately 6 × 105 was inoculated and incubated 
at 37°C for 24 h. CFU per milliliter was determined at 0, 3, 6, 
and 24  h of incubation. For determining CFU per milliliter of 
the organism, 0.1  ml aliquots from each tube were transferred 
to 10 ml normal saline, serially diluted, and plated onto nutrient 
agar in duplicates. Counts were obtained by multiplying the aver-
age number of colonies from the duplicate plates by the dilution 
factor. Synergy was interpreted as more than 2 log10 reductions 
in the CFU per milliliter in the tube containing both drugs com-
pared to the most active single agent.
statistical Methods
Frequency distribution was done for categorical variables and 
descriptive statistics such as mean, median, SD, and minimum 
and maximum for continuous variables. Independent sample 
t-test was used to find the difference in the biofilm between the 
blood and the sputum isolates. Association between motility 
status (NM/IM/HM) and the isolates (blood/sputum) was calcu-
lated using chi square test. Histogram, error plot, and clustered 
bar chart were also used for data presentation.
resUlTs
In this study, we employed 60 clinical A. baumannii strains 
isolated from 60 different patients from a tertiary care facility 
in Southern India (Tamil Nadu). The age of the patients varied 
from newborn to 74 years and roughly 30% were female patients. 
Among the isolates, half of them were from sputum samples 
and the other half were isolated from the blood cultures. All the 
isolates displayed resistance to multiple antibiotics including 
broad-spectrum-β-lactams, such as cefepime, imipenem, and 
meropenem (data not shown). We then investigated the clonal 
groupings among the isolates by determining the presence of 
blaOXA-51-like, csuE, and ompA allelic variants using Group 1 PCR, 
as described by Turton and colleagues (39). We found that 21 
(70%) sputum isolates and 17 (57%) blood isolates showed 
characteristic amplification patterns of European clonal group II 
(ECII, Table 1). Only one sputum isolate and two blood isolates 
displayed a PCR profile similar to European clonal group III 
(ECIII, Table 1). The rest of isolates generated patterns that were 
outside the pan-European clonal lineages I-III. Based on the PCR 
amplification pattern, these non-European clones can be divided 
into four categories: UC-I through -IV (Table 1). We observed 
that sputum samples are less diverse, containing only the UC-II 
(only ompA and blaOXA-51-like amplification) and UC-IV groups 
(only blaOXA-51-like amplification). On the other hand, blood isolates 
were more diverse containing all four UC types.
To understand more about the MDR properties of these iso-
lates, we first verified whether MBLs are involved in the resistance 
toward β-lactam antibiotics. For this, we performed disk diffu-
sion assays using EDTA to distinguish MBL producing isolates, as 
described previously (40). We found that 16 isolates from sputum 
and 16 isolates from blood were MBL-positive (Table 1). We then 
checked the presence of New Delhi metallo-β-lactamse (NDM-1) 
among the isolates by PCR. We found two blood isolates (B11911 
and B5208) and four sputum isolates were NDM-1 positive 
(SP1917, SP1909, SP1851, and SP1843). Among the two blood 
isolates, one belongs to EC-II (B5208) and the other to UC-I 
(B11911). On the other hand, all sputum isolates were from the 
clonal lineage EC-II. With the rest of the MBL-positive isolates, 
we also checked for the presence of VIM-1 and found none of the 
TaBle 1 | Phenotypic properties of the (a) blood isolates and (B) respiratory isolates.
sample iD age/sex clone group# Biofilm* Motility@ (mm) Mic$ synergy+
Mer sUl cOl M + s c + s
(a) Phenotypic properties of the blood isolates
B21029E 25FT EC-II(OEX) 1.61 ± 0.09 10 128 64 0.25 INDa* INDb*
B10883E 4F UC-I 1.95 ± 0.18 >40 64 64 1.0 INDa* INDc*
B29276 0MIV EC-II(OEX) 2.08 ± 0.85 20 16 32 0.5 INDb IND
B25330 0MT EC-III(EX) 2.20 ± 0.71 25 64 64 0.5 INDb* INDc*
B28412 0MT UC-II(OX) 1.01 ± 0.68 <5 32 32 0.5 SYNb* INDc*
B28641E 74MIV UC-III(X) 2.68 ± 0.30 30 64 64 0.5 SYNa* SYNb*
B13833E 75MIV UC-IV(O) 1.03 ± 0.14 35 32 32 0.5 SYNb* INDc*
B1301 54FT,IV UC-I 2.58 ± 0.20 35 128 128 0.5 SYNa INDb,c*
B29819 25M EC-II(OEX) 2.11 ± 0.09 20 128 128 0.5 SYNb* SYNc*
B11439E 45FT EC-II(OEX) 3.11 ± 0.35 10 64 32 0.5 INDb* SYNb*
B27768 50MT EC-II(OEX) 0.73 ± 0.08 10 128 32 0.5 INDa* INDc*
B10631E 13MIV UC-II(OX) 2.06 ± 0.23 10 64 64 0.5 INDb* INDb*
B4609E 13FT,IV EC-II(OEX) 2.15 ± 0.20 25 16 32 0.5 SYNb* INDc*
B27683E 2M UC-V(EO) 3.00 ± 0.48 20 64 32 0.5 SYNa* INDc*
B29467 65M EC-III(EX) 2.43 ± 0.40 >40 64 32 0.5 SYNb* SYNc*
B27919E 34MT,IV EC-II(OEX) 2.45 ± 0.01 10 64 64 0.5 INDa* INDc*
B28414E 74MIV EC-II(OEX) 2.25 ± 0.15 <5 64 64 1.0 SYNb* INDb*
B23356 9MT,IV UC-IV(O) 1.23 ± 0.18 >40 64 32 1.0 INDa INDc*
B8689 41MT,IV UC-IV(O) 0.73 ± 0.02 >40 128 128 0.5 SYNb* INDa*
B17606E 14MT,IV EC-II(OEX) 1.97 ± 0.00 10 64 128 0.5 INDa* INDc*
B8716E 1M EC-II(OEX) 1.61 ± 0.45 10 128 64 0.25 INDa INDc*
B8765 45MT UC-II(OX) 1.24 ± 0.22 <5 256 64 0.5 INDa* INDc*
B11911E/N 45MIV UC-I 2.44 ± 0.78 10 256 64 0.5 IND SYN
B5534 21FT EC-II(OEX) 3.86 ± 0.89 >40 256 64 1.0 SYNb* INDc*
B5208E/N 47M EC-II(OEX) 3.09 ± 0.14 25 128 64 0.5 SYNa* SYNb*
B5586 2FT,IV EC-II(OEX) 2.03 ± 0.20 >40 512 128 1.0 INDa* INDc*
B5868 17MT EC-II(OEX) 1.46 ± 0.41 10 256 64 0.5 SYNb* INDc*
B7370E 24F EC-II(OEX) 1.46 ± 0.10 10 256 64 0.5 SYNa* SYNc*
B8240E 58M EC-II(OEX) 2.10 ± 0.37 15 128 64 0.5 INDa INDc
B9464 24FIV EC-II(OEX) 1.83 ± 0.09 <5 256 64 1.0 SYN IND
(B) Phenotypic properties of the respiratory isolates
SP344 18FIV UC-II(OX) 1.78 ± 0.11 20 64 128 0.25 SYNb* INDc*
SP858 25MT UC-II(OX) 1.37 ± 0.07 <5 128 0.25 0.25 SYNb* INDb*
SP1397E 48MT EC-II(OCX) 3.43 ± 0.11 <5 512 128 0.25 INDb* INDc*
SP1115E 62M EC-II(OCX) 4.72 ± 0.44 <5SM 128 64 0.25 SYNb* INDc*
SP1394 61FT,IV EC-II(OCX) 3.82 ± 0.31 10 64 64 0.25 SYNb* INDc*
SP1182 60MT EC-II(OCX) 4.71 ± 0.25 10 128 64 0.25 INDa* SYNc*
SP1974 57FT,IV EC-II(OCX) 3.67 ± 0.08 <5 256 256 1 INDa* SYNc*
SP1128 35MT EC-III(CX) 3.59 ± 0.16 <5 256 128 0.5 SYNa* INDc*
SP1977 61MT,IV EC-II(OCX) 5.01 ± 0.70 10 256 512 0.5 SYNb SYN
SP1054 39FT,IV EC-II(OCX) 3.90 ± 0.10 <5SM 64 64 1 SYNa INDc*
SP1917E/N 68MT,IV EC-II(OEX) 3.62 ± 0.16 <5 512 256 0.25 SYNa* INDb*
SP1209 49 MT,IV EC-II(OCX) 5.51 ± 0.63 <5SM 64 64 0.5 SYNb* SYNc*
SP1201E 55M EC-II(OCX) 3.72 ± 0.12 10 256 32 0.5 INDa* INDb*
SP932E 52M EC-II(OCX) 3.19 ± 0.12 10 256 64 1 SYNa* INDc*
SP2006E 21MIV UC-IV(O) 1.39 ± 0.09 <5 32 64 8 IND SYN
SP443E 59M UC-II(OX) 1.39 ± 0.00 <5 32 32 0.5 SYNa INDc*
SP1022E 65MIV EC-II(OCX) 2.44 ± 0.35 <5 256 64 1 SYNb INDc*
SP1026E 28MT EC-II(OCX) 3.95 ± 0.33 <5 256 32 1 SYNa* INDc*
SP3179 29MT,IV EC-II(OCX) 3.70 ± 0.17 <5 128 64 1 INDb* INDb,c*
SP2200 40MT,IV UC-II(OX) 2.58 ± 0.30 <5 32 16 1 SYNb* INDc*
SP1950 68MT EC-II(OCX) 3.35 ± 0.58 <5 256 256 0.5 SYNb* INDc*
SP715 17MT UC-II(OX) 3.02 ± 0.63 <5 256 32 0.25 SYNb* SYNc*
SP1909E/N 28F EC-II(OCX) 3.50 ± 0.04 10 512 512 0.5 IND SYN
SP1306E 47FIV UC-II(OX) 1.67 ± 0.03 <5SM 32 64 1 INDb INDc*
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(Continued)
sample iD age/sex clone group# Biofilm* Motility@ (mm) Mic$ synergy+
Mer sUl cOl M + s c + s
SP1766E 40MT EC-II(OCX) 6.78 ± 0.33 >40SM 512 64 0.5 SYNa* SYN
SP1834E 50M EC-II(OCX) 3.08 ± 0.28 <5 256 256 0.5 SYN SYN
SP1840E 75M EC-II(OCX) 6.39 ± 0.47 >40SM 512 128 0.5 SYNa* IND
SP1851E/N 48MT,IV EC-II(OCX) 4.87 ± 0.93 <5 512 256 1 IND IND
SP1843E/N 36F EC-II(OCX) 2.89 ± 0.10 <5 256 128 0.5 SYNb* IND
SP1770 24MT UC-II(OX) 2.14 ± 0.08 <5 128 128 0.5 INDa SYN
#Clonal grouping done based on Turton et al. (39). EC, European clone; UC, unknown clone.
The alleles used for clone determination are O, OmpA; E, CsuE, X, Oxa.
*OD580 values of the crystal violet stain eluted from the biofilm biomass grown on polystyrene tubes.
@Twitching motility scored on Petri plates after staining with crystal violet. Diameter of zone of migration is shown.
$MIC determined by microdilution broth method.
+Determined by time-kill assay.
IND = Indifferent; SYN = Synergy.
MER and M = Meropenem; SUL and S = Sulbactam; COL and C = Colistin.
E: MBL-positive as determined by EDTA plate assay.
N: NDM positive isolates as determined by PCR analysis.
Synergism was determined by time-kill assay only.
Explanation for a/a*, b/b*, and c/c* are: a – meropenem, a* – meropenem positive for bactericidal effect; b – sulbactam, b* – sulbactam positive for bactericidal effect; c – colistin, 
c* – colistin positive for bactericidal effect.
T, intubated; IV, intravenous lines; SM, swarming motility.
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isolates were positive for VIM-1. Thus, it is possible that the rest 
of the MBL-positive isolates encode other types of MBL such as 
IMP or SIM. We have recently determined the complete genome 
sequence of B11911 and SP1917 isolates, and we found that both 
the isolates encode the blaNDM-1 gene (41).
Since these isolates were all MDR positive, we then decided to 
determine synergy between sulbactam with either meropenem or 
colistin. For this test, we first determined the MIC50 values for the 
isolates and found that the values are 0.5, 64, and 128 μg/ml for 
colistin, sulbactam, and meropenem, respectively. We then deter-
mined the antibiotic synergy using a time-kill assay. For the blood 
isolates, the sulbactam and meropenem combination resulted in 
synergy on 50% isolates with 82% showing bactericidal activity. 
The sulbactam and colistin combination yielded relatively low 
synergy with only 17% isolates displaying synergy and 96% were 
bactericidal. On the other hand, among the sputum isolates, drug 
synergy was seen among 76% of the isolates when the sulbactam 
and meropenem combination was used. Like in blood isolates, 
synergy was seen only among 15% isolates when the sulbactam 
and colistin combination was used. With both types of isolates, 
we did not observe any antagonistic activity with both the anti-
biotic combinations. Taken together, our results indicate that the 
sulbactam and meropenem combination could be an effective 
alternative treatment strategy for MDR A. baumannii infections, 
while the sulbactam and colisitin combination will not be very 
effective.
One of most important virulence-related attributes of A. bau-
mannii is the ability to form biofilm. Therefore, we decided to 
measure the biofilm forming capacity of these two groups of 
isolates. Since A. baumannii is able to form biofilm on polystyrene 
surfaces (33), we used polystyrene test tubes as an abiotic surface 
for the biofilm growth (Figure 1A). We found that most of the 
isolates from both blood and sputum were able to form varying 
degrees of biofilm on polystyrene. We found that blood isolates 
formed less robust biofilm compared to the sputum isolates, 
which formed thicker biofilm. The OD580 values for the blood 
isolates varied between 0.73 (B8689) to 3.86 (B5534) with major-
ity of the isolates yielding values <2.0. On the other hand, the 
OD580 values for the sputum isolates were between 1.39 (SP443) 
and 6.78 (SP1766), with majority of the isolates yielding values 
above 2.0 (Figure  1B). The difference in the biofilm forming 
capacity was statistically significantly higher (p < 0.001; paired 
Student’s t-test) in the sputum isolates as compared to the blood 
isolates (3.51 ± 1.38 and 2.02 ± 0.73, respectively; Figure 1C). 
We found no correlation between the biofilm forming capacity 
and the MDR phenotypes (p < 0.5). However, the two sputum 
isolates (SP1766 and SP1840) that displayed the highest biofilm 
masses also showed the highest MIC50 values for meropenem 
(512  μg). Interestingly, these two isolates also formed pellicle 
during growth in liquid media; none of the other isolates formed 
pellicle. We did not observe any correlation between the clonality 
of the isolates and the biofilm forming capacity.
Because we found a significant difference in biofilm forming 
capacity, we decided to measure the motility among the isolates. 
We first measured the twitching motility displayed by the isolates. 
Twitching motility was assayed based on the ability of the cells to 
spread on the polystyrene Petri dishes. We found that the isolates 
displayed varying degrees of twitching motility. We categorized 
these isolates into three groups. If the twitching zone diameter 
was <5  mm, the isolate is considered as twitching negative. A 
twitching zone diameter between 5 and 20 mm is considered as 
intermediate while >20  mm of twitching zone was considered 
as highly motile isolate. As shown in Figure 2, the blood isolates 
were much more proficient in twitching motility as compared to 
the sputum isolates, which is statistically significant (p < 0.001). 
Twenty-six out of 30 blood isolates were positive for twitching 
motility with 12 isolates considered as highly motile (Figure 2B). 
Moreover, 6 of the 12 highly motile isolates displayed a zone of 
TaBle 1 | continued
FigUre 2 | Twitching motility displayed by A. baumannii clinical 
isolates. (a) Assays were done using polystyrene Petri dishes by depositing 
inoculum at the interphase between the bottom of the Petri dish and agar. 
Plates were incubated for 48 h and stained with crystal violet after discarding 
the media. The average diameter of the zone of twitching was determined, 
and the isolates are classified as non-motile (NM, <5 mm), intermediately 
motile (IM, 5–20 mm), and highly motile (HM, >20 mm) are shown. 
Representative plates are shown. (B) Bar diagram showing number of 
isolates (X-axis) displaying NM, IM, and HM phenotypes. Experiments were 
repeated four or more times.
FigUre 1 | Biofilm formation by A. baumannii clinical isolates. (a) 
Representative polystyrene tubes with varying degrees of biofilms. Biofilms 
were stained with crystal violet after 2 days of incubation. (B) Quantitation of 
biofilm mass by crystal violet. Bar diagrams showing OD values (x-axis) 
against the number of isolates (y-axis). (c) Statistical analysis of the blood 
and respiratory isolates (p < 0.001). Values for mean and SDs are shown. 
Representations: BLD, blood isolates; RSP, respiratory isolates. Experiments 
were repeated at least three times.
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migration diameter higher than 40 mm. However, none of the 
twitching motility efficient blood isolates displayed any swarm-
ing-like motility on the semisolid plates containing 0.4% agar 
(data not shown). In contrast, less numbers of the sputum isolates 
were motile, only seven isolates displayed intermediate degree of 
motility, and only two isolates were in the highly motile category. 
Interestingly, the two highly motile isolates also formed the high-
est amounts of biofilm mass and pellicle (Table 1) despite the fact 
that growth of these isolates in liquid was similar to others. These 
two isolates also displayed swarming-like motility. Surprisingly, 
we also observed that some of the sputum isolates that were not 
efficient in twitching motility displayed swarming-like motility 
(Table  1). Notably, isolates SP1115, SP1054, and SP1306 were 
positive for swarming-like motility. Taken together, our results 
showed that blood isolates are much more motile compared to 
the sputum isolates.
DiscUssiOn
Clearly, our current study sheds some light on the two important 
aspects of A. baumannii pathogenesis, the ability to form biofilm 
and motility. Although several studies have been performed to 
assay biofilm formation by clinical isolates, none of the studies 
systematically measured or compared biofilm formation in 
sputum against blood isolates. This is the first study to find that 
sputum isolates are mostly non-motile while the blood isolates 
are highly motile. In A. baumannii, several factors determine 
the biofilm-forming capacity. The chaperon/usher system and 
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the OmpA protein are the two most important ones. The csuE 
and ompA genes are also used in determining the clonal groups 
of A. baumannii isolates. We observed that the sputum isolates 
belonging to the clonal lineage II formed robust biofilm compared 
to the rest of the isolates. Therefore, it is possible that the chap-
eron/usher system positively contributes to the biofilm formation 
in the clonal lineage II. However, we did not find any correlation 
between the clonal lineage and biofilm formation among the 
blood isolates. Overall, blood isolates formed less robust biofilm 
compared to the sputum isolates. Although we did not find any 
correlation between the clonal lineage and the biofilm forming 
capacity among the blood isolates, we did observe that the three 
isolates forming the most biofilm biomass all belong to clonal lin-
eage II. Since we obtained ompA amplification for all the isolates 
except four during clonal lineage determination, it is possible that 
OmpA does not play a major role in biofilm formation at least in 
the blood isolates. Alternatively, the genes required for biofilm 
formation are either downregulated or not expressed in the blood 
isolates compared to the sputum isolates.
Among all the isolates, we found that only two isolates pro-
duced thick pellicles, whereas a few others produced very thin 
pellicles. Pellicles are bacterial masses arising at the interface 
between air and liquid during growth. Pellicle formation has been 
studied in many bacteria including Bacillus subtilis, Pseudomonas 
aeruginosa, Shewanella oneidensis, and Vibrio parahaemolyticus 
(42–46). Pellicle formation by the clinical isolates of A. bauman-
nii has been recently studied (47, 48). In one study, about 50 
proteins were found to be differentially expressed in the pellicle 
state (47). It appears that different types of pili, other than csu or 
type IV, are required for bacterial attachment and to maintain 
the entire mass floating on the top of the liquid medium. These 
different pili systems could also contribute to A. baumannii 
persistence in hospital settings. We are currently investigating 
the two respiratory isolates that produced maximum pellicle for 
persistence.
While biofilm-related phenotypes have been studied in 
A. baumannii, very little is known about the motility-related 
phenotypes. To our surprise, we found that the blood isolates 
are more frequently motile compared to the respiratory isolates. 
Motility requires the presence of type IV pili, and it has been 
shown that biofilm-forming cells often downregulate genes 
related to motility in other bacteria (49, 50). Type IV pilus 
biogenesis is not well studied in A. baumannii. In Pseudomonas 
spp., nearly 50 genes are involved in the regulation and bio-
genesis of type IV pili (51, 52). We speculate that the reason 
behind the blood isolates displaying high motility is due to 
over expression of type IV pili-related genes as compared to 
the sputum isolates. Alternatively, respiratory isolates that 
display little or no motility might be lacking type IV biogenesis 
genes. Recent comparative genomic studies have confirmed 
certain strain-specific variations in the type IV pili encoding 
genes among various A. baumannii isolates (53). Furthermore, 
Eijkelkamp and colleagues have recently shown that the gene 
encoding the major pilin subunit, pilA, is highly variable among 
the A. baumannii clinical isolates (33). Thus, it is possible that 
pilA alleles determine the degree of motility.
We found that only six isolates, all from respiratory samples, 
displayed swarming-like motility (Table  1). A recent study 
claimed that nearly all the clinical isolates from geographically 
diverse locations displayed swarming-like motility on 0.5% 
agarose-containing media (54). However, another study reported 
that swarming-like motility is about 8%, similar to what we found 
(10% considering both blood and respiratory isolates). There are 
several reasons that can account for this apparent discrepancy, 
including experimental conditions (media and the matrix), 
source and the nature of the isolates, and other external factors. 
Furthermore, both swarming-like and twitching motility are 
regulated by various environmental factors including stress, light, 
and temperature (32, 34, 55, 56). Thus, a slight variation of any 
of these physical factors could have a huge affect on both types 
of motility.
The exact reasons why respiratory isolates frequently form 
more biofilm and are less motile are currently unknown. We 
speculate that A. baumannii strains need to attach firmly to 
the alveolar cells, so that they can invade the host easily. The 
more motile isolates will not have sufficient time for invasion. 
Motility also requires synthesis of 1,3-diaminopropane (DAP), a 
polyamine produced by A. baumannii that is required for motil-
ity (54). It is possible that oxygen-rich environments suppress 
the production of DAP and thus the motility. The oxygen-rich 
environment also generates reactive oxygen species (ROS), and 
a recent study suggests that super oxide dismutase (SOD) is 
required for A. baumannii motility (56). Thus, it is also possible 
that ROS might inhibit biogenesis of type IV pili and other factors 
required for motility. We are currently studying the role of oxygen 
in A. baumannii motility with a few isolates.
In conclusion, this is the first systematic study involving two 
types of A. baumannii clinical isolates, blood and respiratory, to 
correlate with the capacity to form biofilm and motility traits. 
Our results showed that respiratory isolates form robust biofilm 
but are less motile while the blood isolates are more motile. 
However, we did not observe any correlation between the MDR 
phenotypes and motility or biofilm formation. Since motility was 
very frequent among the blood isolates, mechanistic investigation 
in motility would provide novel therapeutic strategies and control 
of the persistence of this pathogen.
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